Vitamin D Therapy Market By Route of Administration (Oral and Parenteral), By Application (Osteoporosis, Rickets, Autoimmune Disorder and Skin Disease) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

The vitamin D therapy market is expected to reach US$ 4,721.9 million by 2027, up from US$ 1,919.4 million in 2018, with a compounded annual growth rate (CAGR) of 10.6% from 2019 to 2027.

According to the research findings of the International Osteoporosis Foundation (IOF), one in three women and one in five men above the age of 50 are prone to suffer a fracture during their lifetime. Malnourishment, increasing consumption of alcohol and tobacco, and hormonal imbalance are causing bone and skin disorders associated with vitamin D deficiency.

Market Synopsis

An excellent pharmacokinetic and pharmacodynamic drug profile will help the parenteral route register faster growth.

Oral routes of administration reign over the vitamin D therapy market in the present scenario. It is very popular with children due to its ease of administration and is formulated in different sizes and colors, which increase its external aesthetic appeal and hence increase its palatability in children.

It is also beneficial for improving vitamin D levels in adults with no systemic illness. Parenteral routes are gaining traction on account of their inherent features, such as an excellent pharmacokinetic and pharmacodynamic drug profile useful in elderly patients suffering from impaired vitamin D absorption via the gastrointestinal tract.

Increased consumption of vitamin D and calcium-deficient diets, as well as hormonal imbalances, cause osteoporosis and progressive aging in humans.

Osteoporosis is currently dominating the applications segment of the vitamin D therapy market. As per the latest statistics provided by the International Osteoporosis Foundation (IOF), globally, osteoporosis causes 8.9 million bone fractures, occurring every 3 seconds. Increased consumption of calcium and vitamin D-rich diets, as well as hormonal imbalances associated with human aging, are risk factors for osteoporosis.

The occurrence rate is higher in the female population as compared to the male population. Malnutrition is causing rickets in children at an early age in developing and poor countries. Skin diseases are receiving a lot of attention because of the massive loss of ozone layers, which allows harmful U.V. radiation to reach the skin's surface, depleting keratinocytes that are needed for Vitamin D3 synthesis. Skin inflammatory diseases such as atopic dermatitis and psoriasis are associated with depleted levels of skin vitamin D.

Rising osteoporosis and low bone mass prevalence, as well as increased public health awareness, drive market growth in the North American region.

North America currently accounts for 33% of the regional vitamin D therapy market. The major factors influencing its market growth are the rising prevalence of osteoporosis and low bone mass. According to the research findings brought forward by the National Osteoporosis Foundation (NOF), approximately one-half of the total adult population in the United States is suffering from osteoporosis.

Increasing public health awareness in the region will further propel the market's growth. Europe is in second place, holding 30% of the market share, owing to the rising prevalence of skin disorders associated with low serum cholecalciferol levels. Favorable reimbursement scenarios for vitamin D therapy support market growth in the European Region.

Asia Pacific accounts for 20% market share, primarily due to the rising prevalence of malnutrition in children, which causes rickets at an early age. The presence of major players such as GlaxoSmithKline plc, Torrent Pharmaceuticals Ltd., Cadila Healthcare, Alkem Laboratories, etc., drives the market growth in the Asia Pacific region.

Periods of History and Forecast

This research report presents the analysis of each segment from 2017 to 2027,considering 2018as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation for the scope of the report is done by route of administration, application, and geography.

Pharmaceutical companies providing vitamin D therapy are Abbott Laboratories, Inc., Alkem Laboratories, Cadila Healthcare Ltd., GlaxoSmithKline, Plc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Torrent Pharmaceutical Ltd.

Key questions are answered in this report.

• What is the competitive scenario in the vitamin D therapy market?
• What are the latest collaborations and strategic mergers and acquisitions taking place in the vitamin D therapy market?
• What are the disease etiology and prevalence rate associated with bone and skin deformities due to vitamin D deficiency?
• Which risk factors are associated with the occurrence of osteoporosis and rickets?
• What are the different formulation aspects associated with the oral and parenteral routes of administration?
• What will be the market performance in both developed and developing nations?

Frequently Asked Question: